This was initially described in the context of CD22-CAR T cells (particularly with CD4/CD8 T cell selection of the T cell product) for pediatric B-ALL where 32.8% of patients developed HLH-like manifestations prompting the use of anakinra in a subset of patients (18). This evidence concerns the gene CD22 and hemophagocytic syndrome.